2024 Cross-Strait Breast Cancer Forum | Dr. Jian Liu: Building Bridges for Academic Exchange and Exploring New Pathways in Breast Cancer Treatment

2024 Cross-Strait Breast Cancer Forum | Dr. Jian Liu: Building Bridges for Academic Exchange and Exploring New Pathways in Breast Cancer Treatment

The "2024 Cross-Strait Breast Cancer Forum," held alongside the 2024 Academic Annual Meeting of the Breast Disease Branch of the Fujian Medical Association, the 2024 Annual Meeting of the Oncology Physicians Branch of the Fujian Medical Doctor Association, and the Fujian Breast Cancer Prevention and Treatment Workshop, took place from December 13 to 15, 2024, in Fuzhou. The forum brought together renowned experts to discuss the latest advancements in breast cancer and oncology. Oncology Frontier interviewed the forum chair, Dr. Jian Liu from Fujian Cancer Hospital, who shared insights into the event's agenda and its key highlights.
ASH 2024 | Dr. Huaquan Wang: Latest Advances in the Treatment of Low-Risk MDS (Part 2)

ASH 2024 | Dr. Huaquan Wang: Latest Advances in the Treatment of Low-Risk MDS (Part 2)

Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders originating from hematopoietic stem cells, characterized by dysplastic development of myeloid cells, ineffective hematopoiesis, refractory cytopenia, and a potential progression to acute myeloid leukemia (AML). At the 2024 Annual Meeting of the American Society of Hematology (ASH), held from December 7 to 10 in San Diego, numerous studies on MDS were presented, showcasing significant progress in the treatment and prognostic evaluation of low-risk MDS. Oncology Frontier - Hematology Frontier invited Dr. Huaquan Wang from Tianjin Medical University General Hospital to provide expert commentary on the most impactful research in this field, delivering cutting-edge insights to our readers.
ASH 2024 | Dr. Hu Zhou: Exploring the Efficacy and Safety of a Novel SYK Inhibitor in Patients with Relapsed/Refractory ITP

ASH 2024 | Dr. Hu Zhou: Exploring the Efficacy and Safety of a Novel SYK Inhibitor in Patients with Relapsed/Refractory ITP

From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, drawing global experts and scholars to discuss the latest advancements in hematology. In recent years, increasing insights into the pathogenesis of immune thrombocytopenia (ITP) have paved the way for innovative treatment strategies, among which SYK inhibitors have garnered significant attention due to their unique mechanisms of action. At this year’s ASH conference, Dr. Hu Zhou from Henan Cancer Hospital shared his team’s latest findings (711) on this front, offering fresh perspectives for future therapeutic strategies. Hematology Frontier invited Dr. Zhou for an in-depth discussion on his study and its clinical significance.
SABCS 2024 | Dr. Huiping Li & Dr. Hanfang Jiang: Hetrombopag – A New Option for CTIT Treatment in Breast Cancer Patients?

SABCS 2024 | Dr. Huiping Li & Dr. Hanfang Jiang: Hetrombopag – A New Option for CTIT Treatment in Breast Cancer Patients?

The 47th San Antonio Breast Cancer Symposium (SABCS) will be held from December 10 to 13, 2024, in San Antonio, USA. A phase II prospective study led by Professors Huiping Li and Hanfang Jiang from Peking University Cancer Hospital will be presented as a poster (Abstract No: P1-02-12). This study explores the efficacy and safety of hetrombopag monotherapy in treating cancer therapy-induced thrombocytopenia (CTIT) in breast cancer patients. Preliminary findings show that hetrombopag achieves a high treatment response rate, rapidly improves platelet (PLT) levels, and demonstrates excellent efficacy and tolerance without severe adverse events, particularly no thrombosis. These results confirm the potential of hetrombopag as a novel therapeutic option for CTIT in breast cancer patients, providing new evidence-based data. As the research progresses, hetrombopag is expected to play a greater role in improving treatment outcomes for breast cancer patients undergoing antitumor therapy.
ESMO Asia 2024 | Professors Hailiang Zhang and Xiaolin Lu’s Team Unveils Multi-Omics Insights into Translocation Renal Cell Carcinoma (TRCC)

ESMO Asia 2024 | Professors Hailiang Zhang and Xiaolin Lu’s Team Unveils Multi-Omics Insights into Translocation Renal Cell Carcinoma (TRCC)

Translocation renal cell carcinoma (TRCC), though rare, constitutes a significant proportion of kidney cancer cases among young and middle-aged patients. Analyzing its characteristics in depth can aid in accurate diagnosis, treatment planning, and prognosis evaluation. At the 2024 ESMO Asia Annual Meeting in Singapore, a study by the team from Fudan University Shanghai Cancer Center on TRCC was showcased in a poster presentation. Urology Frontier invited Professors Hailiang Zhang and Xiaolin Lu to share key findings from their research.
CCHIO 2024 | Prof. Naoufal Louati: Unlocking the Potential of TCM in Cancer Care and Strengthening China-Morocco Collaboration

CCHIO 2024 | Prof. Naoufal Louati: Unlocking the Potential of TCM in Cancer Care and Strengthening China-Morocco Collaboration

The 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) recently convened in Xi'an, bringing together global experts and scholars to discuss the latest advancements in cancer treatment and foster international cooperation. Among the distinguished participants was Prof. Naoufal Louati, President of the Moroccan Institute of Traditional Chinese Medicine, who delivered a keynote presentation titled "Global Progress on Holistic Cancer Care." Following his address, Oncology Frontier interviewed Prof. Louati to discuss his experience at the conference, his insights into the role of Traditional Chinese Medicine (TCM) in cancer treatment, and the promising prospects for China-Morocco collaboration in cancer research and prevention.